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ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HUMAN HEART-LUNG TRANSPLANTATION: 
A CASE REPORT 
R. Pfitzmann, MD, M. Hummel, MD, O. Grauhan, MD, P. Waurick, MD, R. Ewert, MD, M. Loebe, MD, 
Y. Weng, MD, and R. Hetzer, MD, Berlin, Germany 
The occurrence of acute and chronic graft-versus-host 
disease (GVHD) has been widely described in the litera- 
ture, with nearly 50% of cases occurring after bone 
marrow transplantation. Acute GVHD in thoracic organ 
transplantation has been observed after experimental lung 
transplantation i  animals 1but has not been recognized 
very often in lung and heart-lung recipients, 2-5 although 
donor cells persist in the lungs for up to 6 weeks after the 
operation. Altogether we found only four publications 
with a total of six patients having acute GVHD after 
heart-lung transplantation worldwide. 
We report on a 28-year-old woman with congenital 
ventricular septal defect and Eisenmenger reaction in 
whom acute GVHD developed on the tenth postoperative 
day after successful heart-lung transplantation. Immuno- 
suppressive drug therapy was administered with cyclo- 
sporine, azathioprine, and steroids. Additionally, rabbit 
antithymocyte globulin was administered once at a dose of 
1.5 mg/kg body weight for induction therapy. Blood 
products were not given before, during, or after transplan- 
tation. 
The cytomegalovirus status of the donor and the recip- 
ient were negative. Human leukocyte antigen (HLA) 
match showed conformity of five HLA specificities. With 
the patient receiving sufficient immunosuppression, initial 
manifestations of acute GVHD were a temperature 
higher than 40 ° C and a maculopapular rash for the first 
days. Subsequent manifestations included hematopoietic 
dysfunction (aplastic syndrome) with leukopenia, anemia 
and low platelet count, hepatitis, cardiac irregularity with 
supraventricular nd ventricular arrhythmias, and gener- 
alized central seizures after a few days. Echocardiographic 
findings (early diastolic relaxation time and myocardial 
wall thickness) and the intramyocardial electrocardiogram 
(IMEG) showed no signs of acute rejection. The concen- 
trations of plasma transaminases, serum bilirubin, creati- 
nine, lactate dehydrogenase, creatinine, and myoglobin 
were elevated to very high levels, whereas the number of 
red blood cells, leukocytes, and platelets decreased rap- 
idly, indicating a severe course of unknown disease at that 
time. The skin rash rapidly progressed to a form resem- 
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bling toxic epidermal necrolysis (Lyell syndrome). At this 
point we saw no evidence of localized or generalized viral, 
bacterial, or fungal infection. After the development of 
renal failure and acute shortness of breath, leading to a 
short period of cardiopulmonary resuscitation, continuous 
controlled mechanical ventilation was necessary. Because 
of progressive renal failure, the patient required hemodi- 
alysis. Diagnosis of acute GVHD was confirmed by clini- 
cal implications, skin biopsy from the area of cutaneous 
lesions, and evidence of more than 50% of donor-specific 
lymphocytes in peripheral blood by HLA typing. For 
therapy, additional immunosuppression with rabbit anti- 
thymocyte globulin at a dose of 2.5 mg/kg body weight and 
high-dose steroids were instituted. Although cutaneous 
and hematologic manifestations of acute GVHD im- 
proved during the following days, with augmented qua- 
druple immunosuppressive drug therapy and transfusion 
of blood products for aplastic syndrome, the patient died 
on postoperative day 34 of intracerebral b eeding. 
Acute GVHD may occur as a result of the infusion of 
blood products containing viable lymphocytes, but in this 
case the patient had not received any blood products at 
the time of manifestation ofGVHD. Therefore, the viable 
lymphocytes were considered transplanted with the donor 
organs. 
Acute GVHD in patients receiving thoracic organ 
transplants has been recognized rarely until now. Thus, in 
view of the worldwide increasing numbers of lung and 
heart-lung transplantation, acute GVHD, as yet uncom- 
mon, may become more important in the future. 
The first manifestation of acute GVHD can be the 
development of fever and maculopapular rash, which is 
frequently mistaken for a viral or allergic rash. In due 
course the persistent rash begins to scale, and diarrhea, 
hepatosplenomegaly, jaundice, cardiac irregularity, cen- 
tral nervous system irritability, and pulmonary infiltrates 
may occur at the height of the acute GVHD. 
Once acute GVHD is established, little can be done to 
modify its course. Corticosteroids merely serve to enhance 
the susceptibility to infection. Cytolytic therapy (antithy- 
mocyte globulin) is necessary to destroy donor lympho- 
cytes. On the other hand, this therapy results in further 
suppression of immunity. Cyclosporine, a more specific 
immunosuppressive agent, can also be helpful. After solid 
organ transplantation, the appearance of acute GVHD is 
fatal in the majority of immunosuppressed patients. Be- 
cause treatment isvery difficult, immediate arly diagnosis 
of acute GVHD appears to be essential to institute 
adequate and early therapy and to prevent the severe 
course of this disease, ultimately with the death of the 
patient. 
When characteristic signs appear, such as fever and 
rash, acute GVHD should be considered a possible diag- 
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Fig. 1. Course ofthe number ofwhite blood cells (WBC) and platelets (PLT) during the development of
acute GVHD. 
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Fig. 2. Course of the amount of aspartate aminotransferase (ASAT), creatine kinase (CK), and lactate 
dehydrogenase (LDH) of the patient during acute GVHD. 
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nosis. If acute GVHD is clinically suspected, this may be 
confirmed immediately by skin biopsy and by HLA typing 
of the peripheral blood lymphocytes. Once GVHD is 
documented, aggressive cytolytic therapy to destroy donor 
lymphocytes seems to be the only therapeutic option. 
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RUPTURE OF INFLOW CONDUITS IN THE TCI-HEARTMATE SYSTEM 
Hans H. Scheld, MD, a Rasjid Soeparwata, MD, a Christof Schmid, MD, a Michael Loick, MD, b Michael Weyand, MD, a 
and Dieter Hammel, MD, a Miinster, Germany 
Improved surgical techniques and sophisticated postop- 
erative care have led to impressive long-term results for 
the implantable l ft ventricular assist device (LVAD) as a 
bridge to transplantation in patients with end-stage car- 
diac failure. However, all of the currently used assist 
devices are less than perfect, and only about 70% of 
patients supported with an LVAD eventually undergo 
transplantation. Apart from preoperative multiorgan fail- 
ure, bleeding, thromboembolism, and infection still jeop- 
ardize the successful outcome and contribute to significant 
postoperative morbidity, because most of the patients 
have one or more of these adverse vents. We report on a 
life-threatening complication, which has occurred in two 
of our six patients with the TCI-HeartMate system 
(Thermo Cardiosystems, Inc., Woburn, Mass.) and which 
seems to occur more often than expected) 
Clinical summar ies  
PATIENT 1. A 56-year-old male patient with end-stage 
ischemic heart disease was awaiting heart transplantation. 
Because of recurrent left ventricular decompensation a d 
ongoing New York Heart Association class IV status, we 
decided to implant the TCI system as a bridge to trans- 
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plantation. The patient fulfilled all criteria defined for 
patient selection. The LVAD was implanted with the 
heart beating, as has recently been described for the 
Novacor system (Baxter Healthcare Corp, Novacor Div., 
Oakland, Calif.). 2 Initially, the postoperative course was 
uneventful except for placement of a chest tube for 
left-sided pleural effusion. The patient recovered well, 
with a pump output of 7 to 8 L/rain, and organ function 
steadily improved. He was fully mobile when blood sud- 
denly poured from the cutaneous exit of the drive line on 
postoperative day 22. A chest x-ray film revealed widening 
of the mediastinal structures but otherwise normal find- 
ings. After a sudden drop of the hemoglobin and hemat- 
ocrit levels, the preperitoneal device pocket was reopened 
and massive clots poured out, suggesting severe bleeding. 
Immediate sternotomy was performed and extracorporeal 
circulation was instituted on an emergency basis. A trans- 
verse tear of 2 to 3 mm within the inflow conduit close to 
the proximal edge of the metallic age support, protecting 
the Dacron conduit, became evident. Because of the 
massive blood loss, the left atrial filling pressure decreased 
and air was sucked into the lacerated Dacron tube of the 
inflow conduit. The LVAD was stopped immediately and 
the tear in the inflow conduit closed with felt-patch 
reinforced sutures, French glue, 3" 4 and double wrapping 
with a size 24 Dacron prosthesis. TCI LVAD support was 
reinstituted and no residual leakage was present. Despite 
meticulous deairing of the LVAD, massive cerebral air 
embolism caused brain death during the postoperative 
period. Pathologic examination confirmed rupture of the 
inflow conduit (Fig. 1). 
PATmNT 2. A 35-year-old man with progressive deterio- 
ration as a result of dilative cardiomyopathy and recurrent 
ventricular arrhythmias (Lown IVb) underwent implanta- 
tion of the TCI LVAD system. His condition had deteri- 
orated steadily despite high-dose catecholamine ad- 
